Merck's blockbuster cancer drug, Keytruda, just hit a major legal snag! While a blow for Merck, this setback could be a game-changer for an unnamed rival biotech company.

Experts believe it might weaken Merck's market position, potentially opening doors for competitors to gain access to patients and revenue. This legal twist creates huge opportunities and risks in the competitive oncology market.

Watch this space!